A convicted felon whose insider-trading deal ensnared Martha Stewart is back to his dirty tricks, according to a $4 million lawsuit.
Dr. Samuel Waksal, who ran the ImClone pharmaceutical company, pleaded guilty to fraud in 2003 after tipping off Stewart and other well-heeled pals that his firm’s new cancer drug would not be approved by the FDA.
He’s now at the top of a new Manhattan-based drug company called Kadmon — a name derived from the Jewish tradition of kabbalah. The firm develops drugs that treat cancer and infectious and autoimmune diseases.
A former business associate, Kevin Glodek, charges that Waksal used him to raise capital for the new firm, then cut him out of millions of dollars in promised commissions, according to the civil suit filed Friday in Manhattan Supreme Court.
Glodek, 37, claims he’s owed the $4 million fee from a $40 million transaction in 2012 between Waksal and two investors based on a written agreement.
“Mr. Waksal has continued to live up to his reputation for a lack of integrity when it comes to standard business practices,” Glodek told The Post.
“In this instance, failing to honor his obligation to pay fees earned for professional services.”
The feds recently probed the company for which Glodek works, John Thomas Financial, and its dealings with Waksal, after the price of shares of a drug company Waksal recommended to JTF skyrocketed.
The Post exclusively reported in February that JTF bought stock in the drugmaker Inhibitex shortly before the price rose 150 percent following a deal with Bristol-Myers Squibb.
Waksal had admitted telling JTF about Inhibitex but said that he was merely reading industry trends.
No charges have been brought in connection with the 2012 investigation.
Waksal led a flamboyant lifestyle before spending five years in the clink — dating Martha Stewart’s daughter Alexis, hosting elaborate soirees at his SoHo loft, and popping up in society columns.
A spokesman for Kadmon called the suit “baseless,” adding that his company has not been involved with JTF for a while.